5d 1m 3m 1y 5y 10y
There are no Transcripts on GNMSF.
There are no News articles on GNMSF.
GNMSF vs. ETF Alternatives
Thursday, Apr 174:23 PM
Thursday, Apr 174:23 PM| Comment!
- The FDA approves Glaxo (GSK) and Genmab's (GNMSF) monoclonal antibody Arzerra (ofatumumab) as a first-line therapy for patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
- "Arzerra is the only therapeutic CD20 antibody approved in combination with chlorambucil for first-line CLL and as a monotherapy for CLL refractory to fludarabine and alemtuzumab," says Jan de Winkel, Ph.D., Genmab's CEO.
- In the Phase 3 COMPLEMENT 1 clinical trial the ofatumumab plus chlorambucil group's progression-free survival (PFS) was 22.4 months compared to 13.1 months for the chlorambucil alone group.
Wednesday, May 292013, 3:28 PMGlaxoSmithKline (GSK -3%) says a combination of ARZERRA and chlorambucil has met its primary endpoint of improving progression free survival times (versus treatment with chlorambucil alone) in a pivotal Phase 3 trial with partner Genmab (GNMSF.PK). No unexpected safety issues were encountered. (PR) |Wednesday, May 292013, 3:28 PM| Comment!
Thursday, Aug 302012, 8:16 AMJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR) |Thursday, Aug 302012, 8:16 AM| Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.